Is Nicox S.A. (ALCOX.PA) a Buy, Sell, or Hold?
PAR : ALCOX.PA
Nicox S.A.
$0.3755 EUR
$0.0 (-0.4%)
- Volume
- 96.15K
- Average Volume
- 237.58K
- Market Capitalization
- $30.13M
- P/E Ratio
- -13.70
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.65
- Year Low
- $0.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.18
Company Overview
PAR
Gavin Spencer
Biotechnology
Healthcare
ALCOX.PA
10
FR
EUR
Liquidity Metrics
0.07
4.18
4.18
1.70
0.00
Sales & Valuation
$16.77M
1.80
5.50
0.00
0.00
Profitability
-$0.0274
-$2.41M
-14.39%
-14.39%
-51.16%
-23.26%
P/E Metrics
-13.70
-0.14
-0.14
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-72.51
6/9
$7.78M
$10.37M
$4.35M
-$19.73M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Doug Hubatsch | Executive Vice President & Chief Scientific Officer |
| Gavin Spencer | Chief Executive Officer & Director |
| Sandrine Gestin | Vice President of Finance & Human Resources |
| Jose Boyer | Consultant |
| Ramesh Krishnamoorthy | Senior Director and Head of Late Stage CMC & Quality Control |
Poll Results
No votes yet today — be the first to share your view!
About Nicox S.A. (PAR:ALCOX.PA) Stock
Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric oxide-donating bimatoprost eye drop currently undergoing Phase 3 clinical trials, designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also progressing NCX 4251, a proprietary ophthalmic suspension containing fluticasone propionate nanocrystals, which is in Phase 2b development for the treatment of dry eye disease. Additionally, Nicox has NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, in its preclinical assessment stage. Beyond its pipeline, Nicox markets VYZULTA, a latanoprostene bunod ... ophthalmic solution prescribed for open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution used to alleviate ocular itching linked to allergic conjunctivitis. Established in 1996, Nicox S.A. maintains its headquarters in Valbonne, France.
Frequently Asked Questions
-
What is the current Nicox S.A. (ALCOX.PA) stock price?
-
Nicox S.A.(PAR:ALCOX.PA) stock price is $0.3755 in the last trading session. During the trading session, ALCOX.PA stock reached the peak price of $0.65 while $0.281 was the lowest point it dropped to. The percentage change in ALCOX.PA stock occurred in the recent session was --0.4% while the dollar amount for the price change in ALCOX.PA stock was -$0.0.
-
ALCOX.PA's industry and sector of operation?
-
The PAR listed ALCOX.PA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALCOX.PA?
-
Doug Hubatsch | Executive Vice President & Chief Scientific Officer
Gavin Spencer | Chief Executive Officer & Director
Sandrine Gestin | Vice President of Finance & Human Resources
Jose Boyer | Consultant
Ramesh Krishnamoorthy | Senior Director and Head of Late Stage CMC & Quality Control -
How many employees does ALCOX.PA have?
-
Number of ALCOX.PA employees currently stands at 10. ALCOX.PA operates from 2405 Route Des Dolines, Valbonne, None 06560, FR.
-
Link for ALCOX.PA official website?
-
Official Website of ALCOX.PA is: https://www.nicox.com
-
How do I contact ALCOX.PA?
-
ALCOX.PA could be contacted at phone #33 4 97 24 53 00 and can also be accessed through its website. ALCOX.PA operates from 2405 Route Des Dolines, Valbonne, None 06560, FR.
-
How many shares of ALCOX.PA are traded daily?
-
The average number of ALCOX.PA shares traded daily for last 3 months was 237.58K.
-
What is the market cap of ALCOX.PA currently?
-
The market value of ALCOX.PA currently stands at $30.13M with its latest stock price at $0.3755